Número 1 - EII al día

Revisiones
13. Bernstein LH, Frank MS, Brandt LJ, BoleY SJ. Healing of perineal Crohn´s
disease with metronidazole. Gastroenterology 1980;79:357-65.
14. Turunen U, Frakkila M, Seppala K. Long term treatment of perianal or
fistulous Corhn´s disease with Ciprofloxacin. Scan J Gastroentrol
1989;24(Suppl 158):144.
15. Gisbert J, Gomollón F, Maté J,Pajares JM.Tratamiento farmacológico de
las fístulas en la enfermedad de Crohn . Med Clin. 2001116:664-71.
16. Caprilli R, Gasull MA, Escher JC, Moser G, Munkholm P, Forbes et al. European
Evidence based consensus on the diagnosis and management of
Crohn´s disease : special situations. Gut 2006;55( Suppl I):i36-58.
17. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W.
Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn´s
disease. Aliment Pharmacol Ther. 2003;18:1113-20.
18. Pearson DC, May GR, Fick GH, Sutherland RL. Azathioprine and 6 mercaptopurine
in Crohn´s disease. A meta-analysis. Ann Intern Med
1995;122:132-42.
19. Korelitz BI, Adler DJ, Mendelson RA et al. Long term experience with 6
mercaptopurine in the treatment of Corhn´s disease. Am J Gastroenterol
1993;88.1198-205.
20. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand
RA et al. Infliximab for the treatment of of fistulas in patients with Corhn´s
disease. N Engl J Med 1999; 340:1398-405.
21. Ochsekuhn T, Göke B, Sackmann M. Combining infliximab with 6-mercaptopurine
/ azathioprine for fistula therapy in Crohn´s disease. Am J
Gastroenterol. 2002;97:2022-5.
22. Lemann M, Mary JI, Duclos B, Veyrac M, Dupas JL, Delchier JC et al. Infliximab
plus azathioprine for steroid-depedent Crohn´s disease patients:a randomized
placebo-controlled trial. Gastroenterology 2006;130:1054-61.
23. Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A et al. Recomendaciones
GETECCU-2005 para el uso de infliximab(Remicade(r)) en la
enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2005;28:126-34.
24. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan B, Fedorak R. et
al . Infliximab maintenance treatment for fistulizing Crohn´s disease. N
Engl J Med 2004; 350:876-75.
25. Lichtenstein G, Abreu MT, Cohen R, Tremaine W. American Gastroenterological
Association Institute Technical Review on corticosteroids, immunomodulators
and Infliximab in inflammatory bowel disease. Gastroenterology
2006;130:940-87.
26. Domènech E , Hinojosa J, Nos P, García-Planella E, Cabré E, Bernal I et al.
Clinical evolution of luminal and perianal Corhn´s disease after inducing
remission with Infliximab : how long should patients be treated?. Aliment
Pharmacol Ther 2005;22:1107-13.;348:601.
27. Baert F, Nomam M, Vermeire S, Van Assche G, D´Haens G, Carbonez A
et al.Influence of immunogenicity on the long-term efficacy of infliximab
in Crohn´s disease. N. Engl J Med. 2003 ;348:601-608.
28. Parsi M, Achkar JP, Richardson S, Katz J, Hammel J, Lashner B et al. Predictors
of response to infliximab in patients with Crohn´s disease. Gastroenterology
2002;123:707-13.
29. Arnott I, McNeill G, Satsangi J. An analysis of factors influencing shortterm
and sustained response to infliximab treatment for Crohn´s disease.
Aliment Pharmacol Ther.2003;17:1451-7.
30. Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J et
al .Demographic and clinical parameters influencing the short-term outcome
of anti-tumor necrosis factor (infliximab) treatment in Crohn´s disease.
Am J Gastroenterol.2002;97:2357-63.
31. West RL, Van der Woude J, Hansen B, Felt-Bersma R, Van Tilburg A,
Drapers J et al. Clinical and endosonographic effects of ciprofloxacin
on the treatment of perianal fistulae in Crohn´s disease with infliximab:
a double-blind placebo-controlledstudy.AlimentPharmacol Ther.
2004,20:1329-36.
32. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn´s disease
with infliximab alone or as an adjunct to exam under anesthesia with seton
placement. Inflamm Bowel Dis 2003;9:98-103
33. Hinojosa J, Gomollón F, Nos P, Peñate M, Ceballos D, Gassull MA. Forweek
results of adalimumab treatment in subjects with fistulizing Crohn´s
disease who have failed response or showed intolerance to Infliximab.
Gastroenterology 2006;AGA 2006.
34. Sandborn W, Present D, Isaacs K, Wolf D, Greenberg E, Hanauer et al.
Tacrolimus for the treatment of fistulas in patients with Crohn´s disease:a
randomized ,placebo-controlled trial. Gastroenterology
2003;125:380-8.
35. González-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla
J et al. Long-term tacrolimus therapy in refractory to infliximab
fistulizing Crohn´s diseases. A pilot study. Inflamm Bowel
Dis.2005;11:8-15.
36. Casson DH, Eltumi M, Tomlin S, Walker-Smith J, Murch SH. Topical tacrolimus
may be effective in the treatment of oral and perineal Crohn disease.
Gut 2000; 47:436-40.
37. Stringer E, Thomas JN, Armstrong D. Efficacy of topical metronidazole (
10 percent) in the treatment of anorectal Crohn disease. Dis Colon Rectum
2005;48: 970-4.
38. Poggioli G, Laureti S, Pierangeli F, Rizzello F, Ugolini F, Gionchetti P et al.
Local injection of Infliximab for the treatment of perianal Crohn disease.
Dis Colon Rectum 2005; 48:768-74.
39. Mahadevan U, Marion JF, Present D. Fistula response to methotrexate
in Crohn´s disease: a case series. Aliment Pharmacol Ther.
2003;18:1003-8.
40. García-OlmoD, García-Arranz M, Herreros D, Pascual I, Peiro C ,Rodríguez-
Montes JA. A phase I clinical trial of the treatment of Crohn´s fistula by
adipose mesenchymal stem cell transplantation. Dis Colon Rectum.2005;48:1416-32.
41. Singh B, Mortensen NJ, Jewell DP, George B. Perianal Crohn’s disease. Br
J Surg. 1994;91:801-14.
42. Whiteford MH, Kilkenny J, Hyman N, Buie D, Cohen J, Orsay C et al. Practice
Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano
(Revised). Dis Colon Rectum 2005;48:1337-42.
23 • Enfermedad Inflamatoria Intestinal al día - Vol. 6 - Nº. 1 - 2007